NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey

Basit Öğe Kaydı
dc.authoridALTUNCEKIC YILDIRIM, ARZU/0000-0003-1141-9838
dc.authoridALTINTAS, ENGIN/0000-0003-0796-1456
dc.authoridSirin, Goktug/0000-0002-6945-3193
dc.authoridSAYAN, MURAT/0000-0002-4374-7193
dc.contributor.authorSayan, Murat
dc.contributor.authorYildirim, Figen Sarigul
dc.contributor.authorAkhan, Sila
dc.contributor.authorYildirim, Arzu Altuncekic
dc.contributor.authorSirin, Goktug
dc.contributor.authorCabalak, Mehmet
dc.contributor.authorDemir, Mehmet
dc.date.accessioned2024-09-18T20:26:41Z
dc.date.available2024-09-18T20:26:41Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives: Chronic hepatitis C (CHC) is now a more curable disease with new direct acting antivirals (DAA). Although high sustained virologic response rates, failures still occur in DAA regimens. Our objective in this study was to characterize the real-life presence of clinically relevant resistance - associated substitutions (RASs) in the HCV NS5A gene in CHC patients whose DAA regimen has failed. Methods: The study enrolled 53 CHC patients who experienced failure with DAA regimen as the prospective longitudinal cohort between 2017-2019. Genotypic resistance testing was performed via the viral population sequencing method and The Geno2pheno HCV tool was used for RAS analysis. Results: The most frequent failure category was relapse (88%) followed by non-responder (12%). For a total of 36% of patients, RASs was detected in NS5A, Y93H was the most detected RAS in GT1b infected patients (89%). Conclusions: This study establishes an HCV failure registry for Turkey in which samples were combined with clinical, virologic and molecular data of adult patients whose DAA therapy failed. RASs can occur in CHC patients with DAA treatment failures. Evaluation of RAS after DAA failure is very important before retreatment is initiated to prevent virologic failure. (C) 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.en_US
dc.identifier.doi10.1016/j.ijid.2020.03.061
dc.identifier.endpage89en_US
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.pmid32302766en_US
dc.identifier.startpage84en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijid.2020.03.061
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10481
dc.identifier.volume95en_US
dc.identifier.wosWOS:000540737100014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofInternational Journal of Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Cen_US
dc.subjectHepatitis C virusen_US
dc.subjectNS-5 proteinen_US
dc.subjectTreatment failureen_US
dc.subjectSequence analysisen_US
dc.titleNS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
391.57 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu